Treatment for life for severe haemophilia A. A cost-utility model for prophylaxis vs. on-demand treatment

被引：0
|
作者：
Farrugia, A. [1 ]
Bansal, M. [1 ]
Cassar, J. [2 ]
Kimber, M. C. [1 ]
Auserswald, G. [3 ]
Fischer, K. [4 ]
O'Mahony, B. [5 ]
Noone, D. [5 ]
Tolley, K. [6 ]
机构：
[1] Plasma Prot Therpeut Assoc, Annapolis, MD USA
[2] Almar Therapeut, Canberra, ACT, Australia
[3] Klinikum Bremen Mitte, Prof Hess Kinderklink, Bremen, Germany
[4] Univ Med Ctr Utrecht, Van Creveldkliniek, Utrecht, Netherlands
[5] Irish Haemophilia Soc, Dublin, Ireland
[6] Tolley Hlth Econ, Derby, England
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2013年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：353 / 354
页数：2
相关论文
共 50 条
  • [1] Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment
    Farrugia, A.
    Cassar, J.
    Kimber, M. C.
    Bansal, M.
    Fischer, K.
    Auserswald, G.
    O'Mahony, B.
    Tolley, K.
    Noone, D.
    Balboni, S.
    [J]. HAEMOPHILIA, 2013, 19 (04) : e228 - e238
  • [2] COST-UTILITY OF PROPHYLAXIS VS. ON-DEMAND TREATMENT IN SEVERE HAEMOPHILIA A PATIENTS
    Gharibnaseri, Z.
    Davari, M.
    Cheraghali, A.
    Eshghi, P.
    Ravanbod, R.
    Spendar, R.
    Khedmati, J.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A591 - A591
  • [3] Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia
    Miners, AH
    Sabin, CA
    Tolley, KH
    Lee, CA
    [J]. PHARMACOECONOMICS, 2002, 20 (11) : 759 - 774
  • [4] Cost-Utility Analysis of Primary Prophylaxis versus Treatment On-Demand for Individuals with Severe Haemophilia
    Alexander H. Miners
    Caroline A. Sabin
    Keith H. Tolley
    Christine A. Lee
    [J]. PharmacoEconomics, 2002, 20 : 759 - 774
  • [5] Treatment for life: Prophylaxis in haemophilia A is more cost-effective than on-demand therapy in a cost-utility model
    Farrugia, A.
    Cassar, J.
    Kimber, M. C.
    Bansal, M.
    Balboni, S.
    [J]. HAEMOPHILIA, 2012, 18 (05) : 828 - 829
  • [6] Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy
    Coppola, A.
    D'Ausilio, A.
    Aiello, A.
    Amoresano, S.
    Toumi, M.
    Mathew, P.
    Tagliaferri, A.
    [J]. HAEMOPHILIA, 2017, 23 (03) : 422 - 429
  • [7] COST-EFFECTIVENESS OF PROPHYLAXIS COMPARED TO ON-DEMAND TREATMENT IN SEVERE HAEMOPHILIA A. SYSTEMATIC REVIEW
    Odnoletkova, I
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A599 - A600
  • [8] Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A
    Risebrough, N.
    Oh, P.
    Blanchette, V.
    Curtin, J.
    Hitzler, J.
    Feldman, B. M.
    [J]. HAEMOPHILIA, 2008, 14 (04) : 743 - 752
  • [9] Prophylaxis vs. on-demand treatment with Nuwiq® (Human-cl rhFVIII) in adults with severe haemophilia A
    Tiede, A.
    Oldenburg, J.
    Lissitchkov, T.
    Knaub, S.
    Bichler, J.
    Manco-Johnson, M. J.
    [J]. HAEMOPHILIA, 2016, 22 (03) : 374 - 380
  • [10] COST-UTILITY ANALYSIS OF ANTIHEMOPHILIC FACTOR RFVIII-FS FOR SECONDARY PROPHYLAXIS VS ON-DEMAND THERAPY IN SEVERE HAEMOPHILIA A IN ITALY
    Tagliaferri, A.
    Coppola, A.
    Amoresano, S.
    Aiello, A.
    D'Ausilio, A.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A671 - A671
12345